Lexeo TherapeuticsLXEO
LXEO
About: Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Employees: 72
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 9
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
17% more funds holding
Funds holding: 59 [Q2] → 69 (+10) [Q3]
9.54% more ownership
Funds ownership: 80.67% [Q2] → 90.21% (+9.54%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
37% less capital invested
Capital invested by funds: $426M [Q2] → $270M (-$157M) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
203%
upside
Avg. target
$22
256%
upside
High target
$25
298%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 25% 1-year accuracy 41 / 164 met price target | 266%upside $23 | Buy Maintained | 14 Nov 2024 |
Chardan Capital Geulah Livshits 17% 1-year accuracy 8 / 48 met price target | 298%upside $25 | Buy Maintained | 13 Nov 2024 |
Leerink Partners Mani Foroohar 38% 1-year accuracy 6 / 16 met price target | 203%upside $19 | Outperform Maintained | 13 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs.
Neutral
GlobeNewsWire
1 month ago
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025 Appointed Tolga Tanguler to Board of Directors, an accomplished biopharmaceutical executive with over 25 years of senior leadership experience Cash and cash equivalents of $157.0 million expected to provide operational runway into 2027 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today provided business updates across its portfolio of programs and reported third quarter 2024 financial results. “We have made significant progress over the last few months across all our clinical stage programs, including reaching alignment with the FDA on registrational endpoints to support an accelerated approval pathway for LX2006.
Neutral
GlobeNewsWire
1 month ago
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's
Neutral
GlobeNewsWire
1 month ago
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that interim data from the ongoing Phase 1/2 trial (NCT03634007) of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference taking place October 29 - November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2 gene into the central nervous systems of APOE4 homozygotes with Alzheimer's disease.
Neutral
GlobeNewsWire
3 months ago
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences: H.C.
Neutral
GlobeNewsWire
4 months ago
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures
Positive
Seeking Alpha
5 months ago
Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Lexeo Therapeutics, Inc. achieved positive results across two studies using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy; Clinically meaningful improvements observed in several cardiac biomarkers. The global Friedreich's ataxia market is expected to reach $3.39 billion by 2034. Additional interim results, along with cardiac biopsy assessment in FA patients with LX2006, expected at an upcoming medical conference presentation in Fall of 2024.
Positive
Zacks Investment Research
5 months ago
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.
Negative
Benzinga
5 months ago
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Nasdaq Composite rising more than 200 points on Monday.
Negative
Investors Business Daily
5 months ago
Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
Lexeo Therapeutics stock crashed Monday despite promising results for a gene therapy designed to treat heart problems of a genetic condition.
Charts implemented using Lightweight Charts™